LEUVEN MINDGATE

TiGenix successfully completes private placement raising EUR 7.7million


Leuven (BELGIUM) - December 10, 2009 - TiGenix NV (NYSE Euronext Brussels: TIG) announces that it has successfully raised EUR 7.7 million through a private placement.

Today, TiGenix completed the private placement of EUR 7.7 million with Belgian and international institutional and professional investors in the European Economic Area and
Switzerland through the issuance of 2,204,300 shares at an issuance price of EUR 3.5.
The proceeds will be used to fund TiGenix' commercial launch of ChondroCelect and ChondroMimetic and to accelerate the clinical pipeline development.
Payment for and delivery of the new shares is expected to take place on 15 December after which they are expected to be admitted to trading on Euronext Brussels. Following this
transaction, the amount of outstanding ordinary shares will increase to 31,655,188.
Trading of TiGenix shares on Euronext Brussels will resume on 11 December 2009.

Petercam and ING acted as lead managers and joint bookrunners for the offering. KBC Securities acted as co-lead manager.

For more information, please contact:
Gil Beyen
Chief Executive Officer

Frank Hazevoets
Chief Financial Officer
T: +32 16 39 60 60
Investor@tigenix.com

About TiGenix
Based in Leuven, Belgium, TiGenix NV (NYSE Euronext Brussels: TIG) is a biomedical company that focuses on 'Regenerating Motion'. The company is exploiting the power of Regenerative Medicine to develop durable treatments, validated through controlled clinical trials, for damaged and osteoarthritic
joints.

TiGenix is developing a portfolio of products that address specific musculoskeletal problems. The
lead indication among these is cartilage damage, which is a debilitating affliction affecting the mobility
and functioning of patients. Western societies are characterised by ageing populations that place an increasing emphasis on high quality of life and life-long mobility, and, as such, cartilage problems represent a large and growing unmet medical need. Current therapies do not provide satisfying, longterm
durable repair and TiGenix therefore believes there is a need for more effective treatments for cartilage damage.
ChondroCelect®, the company's lead product for cartilage regeneration in the knee, is the first cellbased
product that successfully completed the entire development track from research, over clinical
development to central European registration as a medicinal product. On October 5, 2009 ChondroCelect® received European marketing authorisation as the first approved Advanced Therapy
Medicinal Product (ATMP).

This document contains forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements,
forecasts and estimates can be recognised by the use of words such as, without limitation, 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will' and 'continue'
and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown
risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or
achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix
disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to
the extent required by Belgian law.

Important notices regarding the placing
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not an offer of securities for sale into the United States, Canada,
Australia or Japan.
The new shares have not been and will not be registered under the US Securities Act of 1933, as amended (the 'US Securities Act') and may not be offered or sold in the United States absent
registration or an exemption from registration. The Company does not intend to register any portion of the placing in the United States or to conduct a public offering of securities in the United States.
In relation to each member state of the European Economic Area which has implemented the Prospectus Directive (as defined below) (each, a 'Relevant Member State'), with effect from and
including the date on which the Prospectus Directive is implemented in that Relevant Member State (the 'Relevant Implementation Date'), an offer to the public of any shares which are the subject of the placing (the 'Shares') may not be made in that Relevant Member State, except that, with effect
from and including the Relevant Implementation Date an offer of Shares to the public may be made
in that Relevant Member State at any time:
(i) to qualified investors (as defined in the Prospectus Directive or implementing
legislation in the Relevant Member State) ('Qualified Investors');
(ii) to fewer than 100 natural or legal persons (other than qualified investors as
defined in the Prospectus Directive); or
(iii) in any other circumstances which do not require the publication by the Company
of a prospectus pursuant to Article 3 of the Prospectus Directive.
For the purposes of this provision and when used elsewhere in this announcement, the expression
an 'offer of Shares to the public', or any similar expression, in relation to any Shares in any Relevant
Member State means the communication in any form and by any means of sufficient information on
the terms of the placing and the Shares so as to enable an investor to decide to purchase or
subscribe for the Shares, as the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State and the expression 'Prospectus
Directive' when used in this announcement means Directive 2003/71/EC and includes any relevant
implementing measure in each Relevant Member State.

Subscribe to our newsletter

Stay tuned and get our news in your inbox: subscribe here.

Keep me informed
Follow us